Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898152 | 0.93 | KDM4E (0.42) | HIF1AMEN1KMT2ATSHRKDM4E | |
| SCHEMBL14067462 | 0.93 | HIF1A (0.39) | HIF1AMEN1KMT2ATSHREGLN1 | |
| SCHEMBL4901109 | 0.92 | HIF1A (0.38) | HIF1AMEN1KMT2ATSHRGRIN2B | |
| SCHEMBL16021049 | 0.91 | GRIN2B (0.41) | HIF1AMEN1KMT2ATSHRGRIN2B | |
| SCHEMBL4906329 | 0.91 | HIF1A (0.38) | HIF1AMEN1KMT2ATSHRGRIN2B | |
| SCHEMBL6064605 | 0.90 | MEN1 (0.40) | HIF1AMEN1KMT2ATSHRGRIN2B | |
| SCHEMBL4576410 | 0.89 | MEN1 (0.39) | HIF1AMEN1KMT2ATSHRGRIN2B | |
| SCHEMBL16021048 | 0.89 | MEN1 (0.41) | HIF1AMEN1KMT2ATSHRGRIN2B | |
| SCHEMBL4904302 | 0.89 | HIF1A (0.38) | HIF1AMEN1KMT2ATSHRGRIN2B | |
| SCHEMBL4591069 | 0.87 | MEN1 (0.38) | HIF1AMEN1KMT2AGRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | HIF1A 3129/4885MEN1 4841/4885KMT2A 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.